Invited Speakers

prev next
  • Martina U. Muckenthaler PL01 Regulation of iron metabolism University of Heidelberg, Germany CV Abstract
  • Marcel van den Brink PL02 The role of the intestinal microbiome in cancer immunotherapy Memorial Sloan Kettering Cancer Center, USA CV Abstract
  • Toshio Suda PL03 Recent advance in the hematopoietic stem cell research National University of Singapore, Singapore CV Abstract
  • Taeghwan Hyeon PS01 What can Nano do for Medicine? Seoul National University, Korea CV Abstract
  • Chiaki Nakaseko JS01-1 Clinical researches on POEMS syndrome in Japan International University of Health and Welfare School of Medicine, Japan CV
  • Jin Seok Kim JS01-2 Updates on POEMS syndrome in Korea Yonsei University College of Medicine, Korea CV
  • Hiroshi Handa JS01-3 Therapeutic approach of Waldenström's macroglobulinemia in Japan Gunma University, Japan CV Abstract
  • Hosup Lee JS01-4 Clinical researches on Waldenström's macroglobulinemia in Korea Kosin University College of Medicine, Korea CV Abstract
  • Katy Rezvani JS02-1 NK cells: next generation cell therapies for cancer The University of Texas MD Anderson Cancer Center, USA CV Abstract
  • Seok Jin Kim JS02-2 Treatment of extranodal NK/T-cell lymphoma: Korean Lymphoma Working Party experience Sungkyunkwan University School of Medicine, Korea CV Abstract
  • John DiPersio JS02-3 CART for T cell Malignancies Washington University School of Medicine, USA
  • Deok-Hwan Yang JS02-4 Treatment of peripheral T-cell lymphoma: Korean Lymphoma Working Party experience Chonnam National University Medical School, Korea CV Abstract
  • Nguyen Thi Thao JS03-1 Overview of AA diagnosis and treatment in NIHBT, VietNam National Institute of Hematology and Blood Transfusion, Vietnam CV Abstract
  • Lalita Norasetthada JS03-2 The incidence and real-world outcome of aplastic anemia in Thailand Chiang Mai University, Thailand CV
  • Jun Ho Jang JS03-3 Role of TPO receptor agonists in aplastic anemia treatment Samsung Medical Center, Korea CV
  • Uwe Platzbecker JS04-1 MDS 2023: standards and perspectives Leipzig University Hospital, Germany CV Abstract
  • June-Won Cheong JS04-2 Treatment of MDS: Korean AML/MDS working party experience Yonsei University College of Medicine, Korea CV
  • Lionel Adès JS04-3 Current management for MDS Hopital Saint Louis and Paris University, France CV Abstract
  • Yoo-Jin Kim JS04-4 Genetic alteration in MDS The Catholic University of Korea, Korea CV
  • Mahmood A. Chowdhury JS05-1 Overview of thalassaemia and hemoglobinopathies in Bangladesh Chattogram Maa-O-Shishu Hospital Medical College, Bangladesh CV Abstract
  • Chean Sophal JS05-2 Current situation of thalassemia care in Cambodia National Pediatric Hospital, Cambodia CV Abstract
  • Heewon Chueh JS05-3 Epidemiology and diagnosis of hemolytic anemia in Korea Dong-A University College of Medicine, Korea CV Abstract
  • Geoffrey McDermott CS01-1 Single cell sequencing 10x Genomics, Inc., USA CV Abstract
  • Tabe Yoko CS01-2 Blood disease with AI Juntendo University, Japan CV
  • Gina Sun CS01-3 Discover the unique power of using droplet digital PCR (ddPCR) for hematology-oncology applicationss BioRad, USA CV Abstract
  • Yongkeun Park CS01-4 Holotomography and artificial intelligence: label-free 3D imaging, classification, and inference Tomocube Inc., Korea CV Abstract
  • Bong-Seog Kim CS02-1 A Phase 1a Study of BR101801, PI3Kγδ and DNA PK Triple Inhibitor, in Adult Patients with Advanced Hematologic Malignancies Boryung Co. Ltd., Korea CV Abstract
  • David Simpson CS02-2 BGB-11417 the new Bcl-2 inhibitor, the story so far BeiGene, Ltd., New Zealand CV
  • Jonghwa Won CS02-3 Bispecific antibody : ABL Bio ABL Bio Inc., Korea CV Abstract
  • TBD CS02-4 T cell-based cellular immunotherapy TBD
  • Kelly Walkovich SS01-1 How to diagnosis and treat neutropenia in childhood University of Michigan, USA CV
  • Keon Hee Yoo SS01-2 Updates in the treatment of pediatric relapsed/refractory acute myeloid leukemia Sungkyunkwan University School of Medicine, Korea CV Abstract
  • Micheal Verneris SS01-3 CAR T cells and Acute lymphoblastic leukemia: Current state, challenges and future approaches Children’s Hospital Colorado, USA CV
  • Ralf Küppers SS02-1 Pathogenesis of hodgkin lymphoma University of Duisburg-Essen, Germany CV Abstract
  • Natalie S Grover SS02-2 Emerging cellular therapy in HL The University of North Carolina at Chapel Hill, USA CV Abstract
  • Hyeon-Seok Eom SS02-3 Novel treatment of relapsed/refractory hodgkin lymphoma National Cancer Center, Korea CV Abstract
  • Emma M. Groarke SS03-1 Aplastic anemia: Current management considerations National Institutes of Health, USA CV Abstract
  • Jaroslaw P. Maciejewski SS03-2 Clinical and molecular factors of clonal evolution in aplastic anemia Cleveland Clinic, USA CV
  • Jae Wook Lee SS03-3 Non-transplant therapy for pediatric aplastic anemia The Catholic University of Korea, Korea CV Abstract
  • Rafael Duarte SS04-1 Diagnosis and treatment of TA-TMA; Current challenge and future strategies Hospital Universitario Puerta de Hierro Majadahonda, Spain CV
  • Kathleen Freson SS04-2 Genetics of inherited thrombocytopenia University of Leuven, Belgium CV Abstract
  • Hyun Kyung Kim SS04-3 Advances on pathogenesis and diagnosis of TTP Seoul National University College of Medicine, Korea CV Abstract
  • Roni Shouval SS05-1 Artificial intelligence in hematology: basic concepts Memorial Sloan kettering Cancer Center, USA CV Abstract
  • Valeria Visconte SS05-2 How ML deepens our understanding of hematologic malignancies? Cleveland Clinic, USA CV
  • Jongmun Choi SS05-3 Pitfalls of AI for medical application Green Cross Genome, Korea CV Abstract
  • Niels van de Donk SS06-1 Identification of high-risk multiple myeloma Amsterdam University Medical Center, The Netherlands CV Abstract
  • Sung-Hoon Jung SS06-2 Updated diagnosis and treatment of plasma cell leukemia Chonnam National University Hwasun Hospital, Korea CV Abstract
  • Moshe Gatt SS06-3 Safety and efficacy of locally produced novel BCMA CART cells for relapsed/refractory multiple myeloma and al amyloidosis The Hebrew University of Jerusalem, Israel CV Abstract
  • Yvonne Chen SS07-1 Engineering next-generation T cells for cancer immunotherapy University of California, USA CV Abstract
  • Hyoung Jin Kang SS07-2 Development of CAR-T therapy for acute lymphoblastic leukemia Seoul National University College of Medicine, Korea CV Abstract
  • Hiroshi Fujiwara SS07-3 Updates on the latest developments in CAR-T therapies Mie University, Japan CV Abstract
  • Jill Johnsen SS08-1 Genotyping of hemophilia, why we need it and how we do? Division of Hematology University of Washington, USA
  • Jung Woo Han SS08-2 Value of national cohort registry data of hemophilia Yonsei University College of Medicine, Korea CV
  • Sang Hyuk Park SS08-3 Essentials of laboratory issues in Emicizumab Ulsan University Hospital CV Abstract
  • Sergio Rutella SS09-1 DART therapy for AML John van Geest Cancer Research Centre, UK CV
  • Miriam Y Kim SS09-2 Determining the barriers to successful CAR T cell therapy for AML University of Washington, USA CV Abstract
  • Byung Sik Cho SS09-3 Adoptive T cell transfer of three universal tumor associated antigens-specific T cells for the treatment of AML The Catholic University of Korea, Korea CV Abstract
  • Aly Karsan SS10-1 A transcriptomic approach to clinical diagnosis, prognosis and therapy selection in AML University of British Columbia, Canada CV Abstract
  • Sunghoon Kwon SS10-2 Whole genome sequencing of fluorescence in situ hybridized cells in hematologic malignancies using SLACS Seoul National University, Korea CV Abstract
  • Alexander Hoischen SS10-3 Next generation cytogenetics – optical mapping for comprehensive structural variant detection in hematological malignancies and beyond Radboud University Medical Center, The Netherlands CV Abstract
  • Iwijn De Vlaminck SS11-1 Cell-free DNA profiling for monitoring of complications of hematopoietic cell transplantation Cornell University, USA CV
  • Charles Gawad SS11-2 Microbial cell-free DNA sequencing to predict bloodstream infection in pediatric cancer patients St. Jude Children's Research Hospital, USA
  • Seung-Tae Lee SS11-3 Clinical applications of circulating tumor DNA analysis in lymphoma Yonsei University College of Medicine, Korea CV Abstract
  • Robin Foa SS12-1 Are we moving towards a chemo- and transplant-free management of Ph-positive adult ALL? Sapienza University of Rome, Italy CV Abstract
  • Saar I Gill SS12-2 Development of more-effective CAR T-cell therapy for ALL University of Pennsylvania School of Medicine, USA CV Abstract
  • Jae-Ho Yoon SS12-3 Overcoming high-risk features in adult ALL patients The Catholic University of Korea, Korea CV Abstract
  • William J. Greenleaf SS13-1 Single cell HSPC map Stanford University, USA CV
  • Kyung-Rok Yu SS13-2 Humanized mouse and non-human primate: Animal models for hematopoietic stem cell research Seoul National University, Korea CV Abstract
  • Xinxin Huang SS13-3 What we know about HSC homing? Fudan University, China CV Abstract
  • Richard Rosenquist SS14-1 Translating scientific advances in CLL Karolinska Institute, Sweden CV Abstract
  • Jennifer R. Brown SS14-2 Patient selection for time limited versus continued therapy Dana-Farber Cancer Institute, USA CV
  • Ki-Seong Eom SS14-3 MRD monitoring in CLL Patients The Catholic University of Korea, Korea CV
  • Eun-Ji Choi ES01-1 Asciminib: the first-in-class allosteric inhibitor of BCR/ABL1 kinase University of Ulsan College of Medicine, Korea CV Abstract
  • Jieun Uhm ES01-2 Treatment after failure of frontline therapy of CML-CP including allo-HSCT Hanyang University College of Medicine, Korea CV
  • Jae Joon Han ES01-3 Update on treatment free remission Kyung Hee University College of Medicine, Korea CV Abstract
  • Youngwoo Jeon ES02-1 Intravascular B-cell lymphoma The Catholic University of Korea, Korea
  • Jae-Cheol Jo ES02-2 T-large granular lymphocytic leukemia University of Ulsan College of Medicine, Korea CV
  • Jeong-Ok Lee ES02-3 Lymphomatoid granulomatosis Seoul National University Bundang Hospital, Korea CV
  • Hyewon Lee ES03-1 Sezary syndrome and mycosis fungoides National Cancer Center, Korea CV
  • Hyun Jung Lee ES03-2 Systemic mastocytosis Kyung Hee University College of Medicine, Korea CV Abstract
  • Yoo Jin Lee ES03-3 Plasmacytoid dendritic cell neoplasm University of Ulsan College of Medicine, Korea CV
  • Dong Wook Jekarl ES04-1 Transfusion support for HSCT The Catholic University of Korea, Korea CV Abstract
  • Dae-Hyun Ko ES04-2 Evidence based transfusion threshold University of Ulsan College of Medicine, Korea CV Abstract
  • Eun Jung Baek ES04-3 Current status of manufactured blood cells Hanyang University College of Medicine, Korea CV Abstract
  • Ja Min Byun ES05-1 Setting up the facility for CAR T cell therapy Seoul National University College of Medicine, Korea CV Abstract
  • Jong-Seo Lee ES05-2 Technical aspect of manufacturing CAR T cell product AbClon Inc., Korea CV
  • Jae Won Yoo ES05-3 Managing adverse events of CAR T cell therapy The Catholic University of Korea, Korea CV Abstract
Organized by
Supported by